Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
105.10
-1.52 (-1.43%)
Sep 2, 2026, 11:49 AM EDT - Market open
Dianthus Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 110.55 | 51.09 | 22.79 | 132.33 | 15.37 | 7.64 |
Short-Term Investments | 776.26 | 353.21 | 252.45 | 41.39 | 60.13 | - |
Cash & Short-Term Investments | 886.81 | 404.3 | 275.24 | 173.72 | 75.49 | 7.64 |
Cash Growth | 244.54% | 46.89% | 58.44% | 130.12% | 888.35% | - |
Receivables | 0.11 | 0.05 | 0.81 | 0.48 | 5.64 | 1.48 |
Inventory | 7.83 | 3.03 | 3.04 | 2.16 | 0.82 | 0.24 |
Prepaid Expenses | 2.61 | 1.97 | 1.47 | 1.1 | 0.09 | 0.02 |
Other Current Assets | 0.18 | 0.09 | 0.36 | - | - | 0.01 |
Total Current Assets | 897.54 | 409.44 | 280.9 | 177.45 | 82.03 | 9.39 |
Property, Plant & Equipment | 1.64 | 1.63 | 1.75 | 0.8 | 0.96 | 0.03 |
Long-Term Investments | 304.09 | 110.14 | 81.73 | - | - | - |
Other Long-Term Assets | 10 | 9.72 | 9.63 | 1.15 | 0.12 | 0.03 |
Total Assets | 1,213 | 530.92 | 374.01 | 179.41 | 83.11 | 9.45 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 6.39 | 9.73 | 4.58 | 2.61 | 1.17 | 1.36 |
Accrued Expenses | 24.91 | 19.45 | 13.07 | 6.5 | 6.61 | 3.99 |
Current Portion of Leases | 0.37 | 0.37 | 0.32 | 0.42 | 0.35 | - |
Current Unearned Revenue | 1.52 | 1.19 | 0.48 | 0.1 | 0.1 | - |
Total Current Liabilities | 34.39 | 30.73 | 18.45 | 9.63 | 8.23 | 5.35 |
Long-Term Leases | 0.91 | 1.02 | 1.17 | 0.17 | 0.44 | - |
Long-Term Unearned Revenue | 5.94 | 5.77 | 1.91 | 0.74 | 0.79 | - |
Total Liabilities | 41.25 | 37.52 | 21.53 | 10.54 | 9.45 | 5.35 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.06 | 0.04 | 0.03 | 0.02 | - | - |
Additional Paid-In Capital | 1,602 | 829.6 | 526.73 | 258.23 | 1.66 | 0.14 |
Retained Earnings | -427.78 | -336.73 | -174.39 | -89.42 | -45.87 | -17.39 |
Comprehensive Income & Other | -2.13 | 0.49 | 0.11 | 0.05 | -0.16 | - |
Total Common Equity | 1,172 | 493.4 | 352.48 | 168.87 | -44.37 | -17.25 |
Shareholders' Equity | 1,172 | 493.4 | 352.48 | 168.87 | 73.66 | 4.1 |
Total Liabilities & Equity | 1,213 | 530.92 | 374.01 | 179.41 | 83.11 | 9.45 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.29 | 1.39 | 1.49 | 0.59 | 0.79 | - |
Net Cash (Debt) | 1,189 | 513.04 | 355.48 | 173.13 | 74.7 | 7.64 |
Net Cash Growth | 286.39% | 44.32% | 105.32% | 131.76% | 878.03% | - |
Net Cash Per Share | 25.44 | 13.29 | 10.67 | 33.60 | 85.45 | 1.91 |
Filing Date Shares Outstanding | 55.93 | 44.47 | 32.13 | 29.35 | 4.01 | 4.01 |
Total Common Shares Outstanding | 54.8 | 43.22 | 31.12 | 14.82 | 0.88 | 4.01 |
Working Capital | 863.15 | 378.71 | 262.45 | 167.82 | 73.81 | 4.04 |
Book Value Per Share | 21.39 | 11.42 | 11.33 | 11.40 | -50.69 | -4.31 |
Tangible Book Value | 1,172 | 493.4 | 352.48 | 168.87 | -44.37 | -17.25 |
Tangible Book Value Per Share | 21.39 | 11.42 | 11.33 | 11.40 | -50.69 | -4.31 |
Machinery | 0.79 | 0.6 | 0.39 | 0.28 | 0.17 | - |
Construction In Progress | - | - | - | - | - | 0.03 |